title: Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.
authors.affiliation: Internal Medicine III, Ulm University, Ulm, Germany.|Barts Cancer Institute, Queen Mary University of London, London, UK.
authors.forename: J
authors.initials: J
authors.lastname: Edelmann
authors.affiliation: Internal Medicine III, Ulm University, Ulm, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Tausch
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.|Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.|Division of Hematology and Medical Oncology and The Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.|New York Genome Center, New York, NY, USA.
authors.forename: D A
authors.initials: DA
authors.lastname: Landau
authors.affiliation: Internal Medicine I, University of Cologne, Cologne, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Robrecht
authors.affiliation: Internal Medicine I, University of Cologne, Cologne, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Bahlo
authors.affiliation: Internal Medicine I, University of Cologne, Cologne, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Fischer
authors.affiliation: Internal Medicine I, University of Cologne, Cologne, Germany.
authors.forename: A M
authors.initials: AM
authors.lastname: Fink
authors.affiliation: Internal Medicine III, Ulm University, Ulm, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Bloehdorn
authors.affiliation: Center for Clinical Research, Genomics Core Facility, Ulm University, Ulm, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Holzmann
authors.affiliation: Second Department of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Böttcher
authors.affiliation: Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, USA.
authors.forename: L
authors.initials: L
authors.lastname: Werner
authors.affiliation: Second Department of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Kneba
authors.affiliation: Barts Cancer Institute, Queen Mary University of London, London, UK.
authors.forename: J G
authors.initials: JG
authors.lastname: Gribben
authors.affiliation: Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, USA.
authors.forename: D S
authors.initials: DS
authors.lastname: Neuberg
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
authors.forename: C J
authors.initials: CJ
authors.lastname: Wu
authors.affiliation: Internal Medicine I, University of Cologne, Cologne, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Hallek
authors.affiliation: Internal Medicine III, Ulm University, Ulm, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Döhner
authors.affiliation: Internal Medicine III, Ulm University, Ulm, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Stilgenbauer
mesh_terms: D002999:Clone Cells / Q000187:drug effects / Q000473:pathology; D056915:DNA Copy Number Variations; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D009154:Mutation; D000069283:Rituximab / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D000069283:Rituximab